Overview

• Participants in the 36-week injectable trial lost up to 24.3% of body weight at the highest dose while the oral formulation yielded around 13% reduction over 12 weeks.
• Amycretin harnesses dual agonism of GLP-1 and amylin receptors to regulate appetite and blood sugar in a single molecule.
• Gastrointestinal side effects such as nausea and vomiting were common but were mostly mild to moderate and resolved by the end of treatment.
• Researchers observed no plateau in weight loss, suggesting extended use could drive further reductions.
• Novo Nordisk plans to launch phase 3 trials for both injectable and oral amycretin in 2026 to confirm long-term safety and efficacy.